ACEI and ARB use in CKD has been available for over three decades, but it is still underutilized. Now, a new clinical ...

A new study published in the journal of The Lancet Neurology showed that candesartan 16 mg used daily is a well-tolerated and ...

Type 1 diabetes with CKD is understudied with no advancement of therapy options since the 1990s. The FINE-ONE phase 3 trial addresses a high, unmet need for treatments.

Balcinrenone is similar to finerenone (Kerendia), which is also a nonsteroidal MRA and was approved for the slowing of ...

The phase 2 EXPLORE-CKD trial is examining the efficacy and safety of lorundrostat in addition to SGLT2 inhibitors in patients with hypertension and CKD with albuminuria.

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli ™ , the First FDA-Approved ...

Opening all blocked arteries with stents in patients with a heart attack, known as complete revascularization, reduces the ...

Sparsentan therapy was associated with sustained decline in proteinuria and lower likelihood of progression to kidney failure ...

Opening all blocked arteries with stents in patients with a heart attack, known as complete revascularization, reduces the ...

Opening all blocked arteries with stents in patients with a heart attack, known as complete revascularization, reduces the ...

The use of proton pump inhibitors with anti-cancer therapies was associated with worse survival outcomes in patients with breast cancer. Concomitant use of proton pump inhibitors and other everyday ...

The data were presented in a moderated poster session, “Change is in the Air! New Discoveries in Hypertension Treatment”, at the American Heart Association’s (AHA) Scientific Sessions 2025, taking ...